Feeding strategy during mucositis

No registrations found.

Ethical review	Not applicable
Status	Recruiting
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON29080

Source
NTR

Brief title
MucoNut

Health condition

- Children
- Cancer
- Mucositis
- Nutrition

Sponsors and support

Primary sponsor: University Medical Center Groningen(UMCG), Beatrix Children's Hospital
Source(s) of monetary or material Support: Dutch Cancer Society

Intervention

Outcome measures

Primary outcome

Feeding strategy (tube feeding, tpn) and duration in days

Secondary outcome

- Severity of mucositis measured by plasma citrulline (during regular vena punctures, no extra punctures will be done for study purpose only, the remaining plasma will be used to measure citrulline)

- Number of days of mucositis >grade 1, and the peak severity of mucositis according to the NCI-CTCAE criteria

- Weight, daily

- Number of days with pain and the peak level of pain, daily measured with the VAS/Faces score

- Days of analgesics, and the total amount of analgesics

- The number of infectious complications and number of positive blood cultures

- Length of hospital stay

Study description

Background summary

Since there are no data on children with mucositis, and because of the inconsistency in the available literature and clinical practice, we set up this research project to study which strategy is currently used in the clinical practice in pediatric cancer patients with chemotherapy induced mucositis, how many times a switch to parenteral nutrition is inevitable, and what the consequences of feeding strategies are on clinical outcomes. In a multicenter prospective observational study, children (0-18 yrs of age) admitted to the UMCG or AMC, for treatment of B-NHL, or autologous SCT will be included. Feeding strategy (own intake, tube feeding, tpn) and duration in days will be the main outcome.

Study objective

What is the current feeding strategy in pediatric cancer patients suffering from chemotherapy induced mucositis?

Study design

- after chemotherapy course: daily

Intervention

-

Contacts

Public
Pediatric Oncologist and Hematologist
Hanzeplein 1
W.J.E. Tissing
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614213
Scientific
Pediatric Oncologist and Hematologist
Hanzeplein 1
W.J.E. Tissing
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614213

Eligibility criteria

Inclusion criteria

Children (0-18 yrs of age) admitted to the University Medical Center Groningen (UMCG) or Academic
Medical Center (AMC) Amsterdam, for treatment of B Non Hodgkin lymphoma (B-NHL), or autologous stem cell transplantation(SCT)

Exclusion criteria

-

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Masking:	Open (masking not used)

Control:	N/A , unknown

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	01-01-2015
Enrollment:	15
Type:	Anticipated

Ethics review

Not applicable

Application type:	Not applicable

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL4730
NTR-old	NTR5070
Other	: METc 2014/423

Study results